Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection modelsProgressing a ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that the U.S. Food and Drug Administration (FDA ...

Superbugs are increasingly threatening newborn babies across Southeast Asia, rendering standard antibiotics ineffective ...

"Our study highlights the causes of serious infections in babies in countries across Southeast Asia with high rates of ...

Nandita Vijayasimha, Bengaluru Friday, October 17, 2025, 08:00 Hrs [IST] ...

Due to rising antimicrobial resistance, the treatment of complicated UTIs and acute pyelonephritis is becoming more difficult ...

(Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced efficacy and safety results of the positive pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for ...

Cefiderocol was found to be efficacious in patients with gram-negative bloodstream infections, but more evidence is needed in patients with carbapenem-resistant infections.

Highlights include clinical data from Phase 3 studies in Community Acquired Pneumonia (CABP) and microbiologic data from a Phase 2 study in nontuberculous mycobacterial pulmonary disease (NTM-PD) ...

There has been a cool breakthrough using "useless" gold. Researchers have discovered that gold nanoparticles can increase the ...

New data presented at IDWeek 2025 by Japanese drugmaker Shionogi highlight the real-world effectiveness of cefiderocol in ...